174 related articles for article (PubMed ID: 23451223)
1. Prostatic cell-specific regulation of the synthesis of MUC1-associated sialyl Lewis a.
Chachadi VB; Ali MF; Cheng PW
PLoS One; 2013; 8(2):e57416. PubMed ID: 23451223
[TBL] [Abstract][Full Text] [Related]
2. Comparison of sialyl-Lewis a-carrying CD43 and MUC1 mucins secreted from a colon carcinoma cell line for E-selectin binding and inhibition of leukocyte adhesion.
Zhang K; Baeckström D; Brevinge H; Hansson GC
Tumour Biol; 1997; 18(3):175-87. PubMed ID: 9143414
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell MUC1 and CD43 are glycosylated differently with sialyl-Lewis a and x epitopes and show variable interactions with E-selectin under physiological flow conditions.
Fernandez-Rodriguez J; Dwir O; Alon R; Hansson GC
Glycoconj J; 2001; 18(11-12):925-30. PubMed ID: 12820726
[TBL] [Abstract][Full Text] [Related]
4. Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin.
Barthel SR; Gavino JD; Wiese GK; Jaynes JM; Siddiqui J; Dimitroff CJ
Glycobiology; 2008 Oct; 18(10):806-17. PubMed ID: 18647941
[TBL] [Abstract][Full Text] [Related]
5. Analysis of sialyl-Lewis x on MUC5AC and MUC1 mucins in pancreatic cancer tissues.
Balmaña M; Duran A; Gomes C; Llop E; López-Martos R; Ortiz MR; Barrabés S; Reis CA; Peracaula R
Int J Biol Macromol; 2018 Jun; 112():33-45. PubMed ID: 29408556
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
[TBL] [Abstract][Full Text] [Related]
7. Sialyl-Lewis x and Sialyl-Lewis a are associated with MUC1 in human endometrium.
Hey NA; Aplin JD
Glycoconj J; 1996 Oct; 13(5):769-79. PubMed ID: 8910004
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
9. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
10. Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells.
Zhang K; Baeckström D; Brevinge H; Hansson GC
J Cell Biochem; 1996 Mar; 60(4):538-49. PubMed ID: 8707893
[TBL] [Abstract][Full Text] [Related]
11. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
[TBL] [Abstract][Full Text] [Related]
12. Glycosyltransferases involved in the synthesis of MUC-associated metastasis-promoting selectin ligands.
Chachadi VB; Bhat G; Cheng PW
Glycobiology; 2015 Sep; 25(9):963-75. PubMed ID: 25972125
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers.
Chen Z; Gulzar ZG; St Hill CA; Walcheck B; Brooks JD
Prostate; 2014 Jul; 74(10):1059-67. PubMed ID: 24854630
[TBL] [Abstract][Full Text] [Related]
14. TNFα enhances the motility and invasiveness of prostatic cancer cells by stimulating the expression of selective glycosyl- and sulfotransferase genes involved in the synthesis of selectin ligands.
Radhakrishnan P; Chachadi V; Lin MF; Singh R; Kannagi R; Cheng PW
Biochem Biophys Res Commun; 2011 Jun; 409(3):436-41. PubMed ID: 21596021
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.
Laurenzana A; Balliu M; Cellai C; Romanelli MN; Paoletti F
PLoS One; 2013; 8(3):e58267. PubMed ID: 23469273
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure.
Qiu X; Rong X; Yang J; Lu Y
BMC Ophthalmol; 2019 Feb; 19(1):42. PubMed ID: 30717701
[TBL] [Abstract][Full Text] [Related]
17. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
[TBL] [Abstract][Full Text] [Related]
18. Endothelial-selectin ligands sialyl Lewis(x) and sialyl Lewis(a) are differentiation antigens immunogenic in human melanoma.
Ravindranath MH; Amiri AA; Bauer PM; Kelley MC; Essner R; Morton DL
Cancer; 1997 May; 79(9):1686-97. PubMed ID: 9128983
[TBL] [Abstract][Full Text] [Related]
19. Sialyl-Lewis(x) on P-selectin glycoprotein ligand-1 is regulated during differentiation and maturation of dendritic cells: a mechanism involving the glycosyltransferases C2GnT1 and ST3Gal I.
Julien S; Grimshaw MJ; Sutton-Smith M; Coleman J; Morris HR; Dell A; Taylor-Papadimitriou J; Burchell JM
J Immunol; 2007 Nov; 179(9):5701-10. PubMed ID: 17947642
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
Zhou X; Yang XY; Popescu NC
Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
